Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Multicenter, Open-label, 12-week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype

NCT05630066 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05630066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05630066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Multicenter, Open-label, 12-week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
July 27, 2023
Completion date
December 2, 2025
Enrollment
48 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

angelman syndrome